论文部分内容阅读
目的研究中药防治流感的体外效果。方法采用鸡红细胞凝集实验以及MTT法观察三种常见的代表性预防流感的方药(“扶正”预防类-玉屏风制剂;祛邪预防类-银翘散制剂;外用芳香辟秽类制剂-冰香散)对流感病毒A/FM/1/47(H1N1)鼠肺适应株的预防作用。结果冰香散在最小无毒浓度15.6μg/ml时对流感病毒A/FM/1/47(H1N1)鼠肺适应株有良好的预防作用。银翘散和玉屏风散仅在毒性浓度下对流感有预防作用,无毒浓度下均不能抑制病毒。阳性对照药利巴韦林在0.25～2 mg/ml浓度内均有较好的抑制流感病毒作用。冰香散提前加药,冰香散对病毒的半数抑制浓度(IC50)为5.89μg/ml,治疗指数(TI)为3.28;冰香散与病毒同时加药,冰香散挥发油对流感病毒的直接抑制作用的IC50为9.56μg/ml,TI为2.02。而先加流感病毒吸附后再加冰香散,则未能对流感病毒有抑制作用,其治疗指数TI小于0.05。结论冰香散体外对甲型流感病毒FM1有预防作用。玉屏风散制剂和银翘散制剂仅在毒性浓度下对流感有预防作用,无毒浓度下均不能抑制病毒。其防治流感病毒的作用可能通过体内免疫机制而实现。
Objective To study the in vitro effect of Chinese medicine in preventing and treating influenza. Methods The chicken erythrocyte agglutination test and MTT method were used to observe the three common prescriptions for the prevention of influenza (“Fuzheng” prevention type - Yupingfeng preparation; Quxie powder prevention - Yinqiaosan preparation; topical aromatics preparation - Bingxiang powder) on the influenza A / FM / 1/47 (H1N1) lung-adapted strains of rats. Results Bingxian powder had a good preventive effect on influenza A / FM / 1/47 (H1N1) mouse lung-adapted strains with the minimum non-toxic concentration of 15.6μg / ml. Yinqiaosan and Yupingfeng San only play a preventive role in the influenza virus concentration, non-toxic concentrations can not inhibit the virus. Positive control ribavirin at 0.25 ~ 2 mg / ml concentrations have better inhibition of influenza virus. Bingxian powder is added in advance, the IC50 of Bingxian Powder is 5.89μg / ml, and the treatment index (TI) is 3.28. Simvastatin and Volatile Oil are added simultaneously, The IC50 for direct inhibition was 9.56 μg / ml and TI was 2.02. The first add flu virus adsorption plus Bingxian bulk, then failed to inhibit the influenza virus, the therapeutic index TI less than 0.05. Conclusion Bingxiang powder can prevent influenza A virus FM1 in vitro. Yupingfeng powder preparations and Yinqiao powder only in the toxic concentrations of influenza preventive effect, non-toxic concentrations can not inhibit the virus. Its role in the prevention and treatment of influenza viruses may be achieved through in vivo immune mechanisms.